What is the 13F Pro Quality Score for PTGX?

13F Pro ranks Protagonist Therapeutics, Inc (PTGX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PTGX's current score at https://13fpro.ai/research/PTGX (free sign-up required for the full ranking).

Which hedge funds own the most PTGX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PTGX include BlackRock,, FARALLON CAPITAL MANAGEMENT, UBS Group AG. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/PTGX as soon as new 13F filings post.

Where does 13F Pro source PTGX data?

All Protagonist Therapeutics, Inc fundamentals and ownership data come directly from SEC EDGAR. Protagonist Therapeutics, Inc files with the SEC under CIK 1377121. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PTGX in?

Protagonist Therapeutics, Inc (PTGX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PTGX research updated on 13F Pro?

PTGX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Protagonist Therapeutics, Inc(PTGX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1377121 PTGX stock profile & AI dashboard →

13F Pro Quality Score

24.8/100

Rank #2,572 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

2.0/100

Profitability

7.7/100

Balance Sheet

15.5/100

Earnings Quality

30.0/100

Free Cash Flow

91.8/100

Institutional Flow

51.5/100

Revenue Scale

17.1/100

Dilution Risk

3.1/100

PTGX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Protagonist Therapeutics, Inc (PTGX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PTGX at 24.8/100 on a 32-signal composite quality model, placing it at rank #2,572 of 2,879 stocks — the bottom half of the AI-ranked universe. PTGX scores in the top quartile across free cash flow (91.8). Areas of concern include revenue growth (2.0) and profitability (7.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Protagonist Therapeutics, Inc reports quarterly revenue of $56.4M, net income of $3.8M, free cash flow of $-49.2M. Top institutional holders of PTGX by reported 13-F value include BlackRock,, FARALLON CAPITAL MANAGEMENT, UBS Group AG, based on the most recent SEC filings. PTGX trades on the Nasdaq exchange and files with the SEC under CIK 1377121. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PTGX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Protagonist Therapeutics, Inc directly from SEC EDGAR. Protagonist Therapeutics, Inc's 13F Pro composite quality score has ranged between 8 and 53 since 2026, currently 24.8 — an improving long-term trajectory across 36 quarterly and live scoring snapshots.

✦

Fun facts about Protagonist Therapeutics, Inc

Quirks, history, and lore behind PTGX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in the San Francisco Bay Area · focused on peptide-based medicines.
2
The Numbers
A pre-revenue biotech with a market cap in the low hundreds of millions — its balance sheet is more about R&D burn rate than sales figures.
3
The History
Founded in the mid-2010s, the company was built around proprietary technology for engineering peptide analogs that mimic or block natural gut hormone signals.
4
The Secret
Its pipeline targets hematologic diseases and gastrointestinal disorders — including rare blood conditions driven by overactive hormone receptors in the gut.
5
The Lore
The company's lead programs have targeted polycythemia vera and iron-deficiency anemia, chasing a class of drugs that modulate hepcidin — the master regulator of iron in the body.
6
The Giveaway
Its very name declares its mission: be the hero of the story in drug discovery — a peptide-focused biotech whose ticker and name both put the protagonist front and center.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$56.4M

Net Income

Q1 2026

$3.8M

Free Cash Flow

Q1 2026

$-49.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-89.4% YoY

$46.0MFY 2025

FY19 $231.0KFY22 $26.6MFY24 $434.4MFY25 $46.0M

Net Income

-147.3% YoY

$-130.1MFY 2025

FY19 $-77.2MFY22 $-127.4MFY24 $275.2MFY25 $-130.1M

Operating Income

-162.5% YoY

$-158.1MFY 2025

FY19 $-80.5MFY22 $-131.4MFY24 $252.8MFY25 $-158.1M

EPS (Diluted)

-148.5% YoY

$-2.05FY 2025

FY19 —FY22 $-2.60FY24 $4.23FY25 $-2.05

Total Assets

-10.3% YoY

$668.2MFY 2025

FY19 $154.9MFY22 $247.9MFY24 $744.7MFY25 $668.2M

Total Debt

—FY 2025

FY19 $9.8MFY22 —FY24 —FY25 —

Op. Cash Flow

-68.7% YoY

$57.7MFY 2025

FY19 $-41.5MFY22 $-108.1MFY24 $184.2MFY25 $57.7M

Metric	FY 2025	FY 2024	FY 2022	FY 2019	FY 2018	FY 2017
Revenue	$46.0M -89.4%	$434.4M +1534.4%	$26.6M +11406.9%	$231.0K -99.3%	$30.9M +54.1%	$20.1M
Net Income	$-130.1M -147.3%	$275.2M +316.0%	$-127.4M -65.0%	$-77.2M -98.3%	$-38.9M -5.3%	$-37.0M
Operating Income	$-158.1M -162.5%	$252.8M +292.5%	$-131.4M -63.2%	$-80.5M -90.5%	$-42.3M -11.5%	$-37.9M
EPS (Diluted)	$-2.05 -148.5%	$4.23 +262.7%	$-2.60	—	—	—
Total Assets	$668.2M -10.3%	$744.7M +200.4%	$247.9M +60.0%	$154.9M +11.1%	$139.5M -14.8%	$163.7M
Total Debt	—	—	—	$9.8M	—	—
Operating Cash Flow	$57.7M -68.7%	$184.2M +270.3%	$-108.1M -160.4%	$-41.5M +16.9%	$-49.9M -1390.0%	$3.9M

AI Insight: PTGX Financial Trends

PTGX revenue spiked to $56M in Q1 2026 driving a rare $4M net profit, but operating cash outflows deepened to -$49M — the worst in the dataset.

• Revenue surged to $56M in Q1 2026 from $5M in Q3 2025, the highest quarterly figure outside the Q4 2024 milestone payment.

• Net income turned positive at $4M in Q1 2026, reversing four consecutive quarters of losses averaging -$33M.

• Equity has declined from $689M in Q1 2025 to $655M in Q1 2026, reflecting cumulative net losses eroding the balance sheet.

• Operating cash flow deteriorated to -$49M in Q1 2026, the worst quarterly outflow in the dataset despite the revenue beat.

⚠ Operating cash outflow of -$49M in Q1 2026 diverges sharply from reported net income — working capital or milestone timing warrants scrutiny.

⚠ Revenue remains lumpy; Q4 2024's $171M and Q1 2026's $56M appear milestone-driven. Sustainability of top-line growth is unproven.

⚠ No debt reported across all periods, but equity is steadily shrinking — monitor whether cash burn rate threatens future financing needs.

AI Insight: PTGX Ratio Trends

Q1 2026 marks a rare quarterly profit (NPM 6.7%) after persistent losses, but the TTM picture remains deeply negative at -154.9% NPM.

• Q1 2026 NPM turned positive at 6.7% and ROE reached 2.3%, the first profitable quarter since Q4 2024's anomalous spike.

• TTM operating margin stands at -192.4% and NPM at -154.9%, reflecting sustained losses across the trailing four quarters.

• ROE deteriorated from -6.8% in Q1 2025 to -28.9% in Q4 2025 before recovering to 2.3% in Q1 2026, showing high volatility.

⚠ Q4 2024's outsized profitability (NPM 77.2%) appears to be a one-off; whether Q1 2026 profitability is sustainable remains unconfirmed.

⚠ ROIC remains negative at -2.2% in Q1 2026 despite the profit, signaling capital is not yet being deployed productively.

Get alerted when PTGX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Protagonist Therapeutics, Inc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PTGX

BlackRock, Inc.
$1.0B9,779,369 sh
FARALLON CAPITAL MANAGEMENT LLC
$669.2M6,348,906 sh
UBS Group AG
$545.7M5,177,796 sh
RTW INVESTMENTS, LP
$533.2M5,059,053 sh
WELLINGTON MANAGEMENT GROUP LLP
$379.4M3,599,644 sh
STATE STREET CORP
$328.5M3,116,749 sh
JANUS HENDERSON GROUP PLC
$304.9M2,891,527 sh
JOHNSON & JOHNSON
$258.1M2,449,183 sh
Invesco Ltd.
$228.2M2,164,670 sh
GEODE CAPITAL MANAGEMENT, LLC
$176.0M1,669,371 sh

Fund	Value	Shares
BlackRock, Inc.	$1.0B	9,779,369
FARALLON CAPITAL MANAGEMENT LLC	$669.2M	6,348,906
UBS Group AG	$545.7M	5,177,796
RTW INVESTMENTS, LP	$533.2M	5,059,053
WELLINGTON MANAGEMENT GROUP LLP	$379.4M	3,599,644
STATE STREET CORP	$328.5M	3,116,749
JANUS HENDERSON GROUP PLC	$304.9M	2,891,527
JOHNSON & JOHNSON	$258.1M	2,449,183
Invesco Ltd.	$228.2M	2,164,670
GEODE CAPITAL MANAGEMENT, LLC	$176.0M	1,669,371

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PTGX on your watchlist

Track score changes the day Protagonist Therapeutics, Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PTGX a good stock to buy?

13F Pro's AI-powered analysis of Protagonist Therapeutics, Inc (PTGX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PTGX are available on the PTGX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PTGX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PTGX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Protagonist Therapeutics, Inc's investment landscape.